A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of Head and Neck, Lung, or Esophagus
ID Number 14-1977Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called Selinexor (KPT-330). KPT-330 is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA), Health Canada, or the European Medicines Agency (EMA).
Cancer is the uncontrollable growth of human cells. The growth of normal human cells is controlled by multiple mechanisms. Cancer cells can escape one or more of these control mechanisms leading to uncontrollable growth. one specific way cancer cells continue to grow is by getting rid of certain proteins called "tumor suppressor proteins" that would normally cause cancer cells to die.
This study drug KPT-330 works by trapping "tumor suppressing proteins" within the cell and thus causing the cancer cells to die or stop growing.
KPT-330 has previously been tested in humans to define a safe dose to be administered. It is not known if KPT-330 will treat your cancer. KPT-330 is currently being tested in other clinical trials in patients with advanced cancers. This study will examine the effects of KPT-330 on your cancer and on your body including any side-effects that you may experience.
Recruiting Patients: No